Hostname: page-component-586b7cd67f-vdxz6 Total loading time: 0 Render date: 2024-11-28T16:16:59.801Z Has data issue: false hasContentIssue false
  • English
  • Français

Treatment duration of psychiatric disorders: long-term treatment of resistant schizophrenia

Published online by Cambridge University Press:  16 April 2020

JM Kane
JM Kane*
Affiliation:
Department of Psychiatry, Hillside Hospital, A Division of Long Island Jewish Medical Center, Glen Oaks, New York; Albert Einstein College of Medicine, Bronx, New York, USA
*
Correspondence and reprints: Hillside Hospital, PO Box 38, Glen Oaks, NY 11004, USA
Get access

Summary

Although antipsychotic medications are extremely valuable in both the acute and long-term management of schizophrenia, a substantial subgroup of patients derive little or only partial benefit. A variety of strategies to treat such patients are reviewed.

Keywords

schizophreniapsychopharmacologytreatment
Type
Review
Information
European Psychiatry , Volume 8 , Issue 6 , 1993 , pp. 281 - 283
Copyright
Copyright © Elsevier, Paris 1993

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Alvir, J, Lieberman, J, Safferman, A, Schwimmer, JL, Schaaf, JA (1993) Clozapine-induced agranulocytosis: U.S. incidence and risk factors. N Engl J Med 329, 162–167CrossRefGoogle ScholarPubMed
Christison, GW, Kirch, DG, Wyatt, RJ (1991) When symptoms persist: choosing among alternatives somatic treatments for schizophrenia. Schizophren Bull 17, 217–246CrossRefGoogle Scholar
Cole, JO (1964) Phenothiazine treatment in acute schizophrenia. Arch Gen Psychiatry 10, 246–261Google Scholar
Kane, JM, Honigfeld, G, Singer, J, Meltzer, H (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45, 789–796CrossRefGoogle ScholarPubMed
Kane, JM (1990) The efficacy of clozapine in the treatment of schizophrenia: a long-term perspective. J Clin Psychiatry Mono 8, 9–14Google Scholar
Kinon, BJ, Kane, JM, Johns, J, Perovich, R, Ismi, M, Koreen, A, Weiden, Ρ (1993) Treatment of neuroleptic resistant schizophrenic relapse. Psychopharmacol Bull (in press)Google Scholar
Levinson, DF, Simpson, GM, Singh, H, Yadalam, K, Jain, A, Stephanos, MJ, Silver, Ρ (1990) Fluphenazine dose, clinical response and extrapyramidal symptoms during acute treatment. Arch Gen Psychiatry 47, 761–768CrossRefGoogle ScholarPubMed
Rifkin, A, Doddi, S, Karagi, B, Borenstein, M, Wachspress, M (1991) Dosage of haloperidol for schizophrenia. Arch Gen Psychiatry 48, 166–170CrossRefGoogle Scholar
Salzman, C (1980) The use of ECT in the treatment of schizophrenia. Am J Psychiatry 137, 1032–1041Google ScholarPubMed
Van Putten, T, Marder, SR, Mintz, J (1990) A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry 47, 754–758CrossRefGoogle ScholarPubMed
Volavka, J, Cooper, T, Czobor, P, Bitter, I, Meisner, M, Laska, E, Gastanaga, P, Krakowski, M, Chou, JCY, Crowner, M, Douyon, R (1992) Haloperidol blood levels and clinical effects. Arch Gen Psychiatry 49, 354–361CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.